Brief: Atara Biotherapeutics Submits Tabelecleucel (Tab-Cel®) Biologics License Application

Atara Biotherapeutics

20/05/2024 14:30

May 20 (Reuters) - Atara Biotherapeutics Inc  ATRA.O :
    * ATARA BIOTHERAPEUTICS SUBMITS TABELECLEUCEL (TAB-CEL®)
BIOLOGICS
LICENSE APPLICATION FOR TREATMENT OF EPSTEIN-BARR VIRUS POSITIVE
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE WITH U.S. FDA
    * ATARA BIOTHERAPEUTICS INC - ACCEPTANCE OF BLA WILL TRIGGER
$20
MILLION MILESTONE PAYMENT FROM PIERRE FABRE LABORATORIES
    * ATARA ELIGIBLE FOR ADDITIONAL $60M UPON FDA APPROVAL

Source text for Eikon:  ID:nBw7n40HMa 
Further company coverage:  ATRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))